Halozyme Therapeutics | HALO - Trade Debtors

Stock Price
68.60
Daily Change
1.16 1.72%
Monthly
-1.39%
Yearly
28.34%
Q2 Forecast
65.77

Halozyme Therapeutics reported $457.99M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amarin USD 126.83M 477K Dec/2025
Amgen USD 9.14B 432M Mar/2026
Baxter International USD 1.7B 310M Mar/2026
Cara Therapeutics USD 2.24M 2.26M Mar/2025
Cytokinetics USD 6.83M 10.94M Mar/2026
DBV Technologies USD 15.97M 279K Sep/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Halozyme Therapeutics USD 457.99M 16.72M Mar/2026
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 74M 8M Mar/2026
MannKind USD 28.14M 10.23M Mar/2026
Nektar Therapeutics USD 1.78M 1.12M Dec/2025
Pfizer USD 16.17B 332M Mar/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
United Therapeutics USD 312M 38.2M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024